2022
Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
Shen M, Nargesi A, Nasir K, Bhatt DL, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States. Journal Of The American Heart Association 2022, 11: e026075. PMID: 36102276, PMCID: PMC9683659, DOI: 10.1161/jaha.122.026075.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyIcosapent ethylCardiology/American Heart Association (ACC/AHA) guideline recommendationsNutrition Examination Survey dataAddition of ezetimibeUse of statinsClinical practice guidelinesCurrent statin usePopulation health outcomesConclusions SixCardiovascular outcomesStatin useClinical profileGuideline recommendationsLipid profileNational HealthPCSK9iNovel therapiesNovel agentsPractice guidelinesUS adultsAmerican CollegeStatinsHealth outcomesTherapy
2014
“Inflammation and arterial stiffness in humans”
Jain S, Khera R, Corrales–Medina V, Townsend RR, Chirinos JA. “Inflammation and arterial stiffness in humans”. Atherosclerosis 2014, 237: 381-390. PMID: 25463062, DOI: 10.1016/j.atherosclerosis.2014.09.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPrimary inflammatory diseaseArterial stiffnessArterial stiffeningInflammatory diseasesPrimary inflammatory conditionsAnti-inflammatory interventionsRole of inflammationAnti-inflammatory therapyEffect of statinsEffects of inflammationPotential therapeutic targetCardiovascular morbiditySubclinical inflammationInflammatory conditionsGeneral populationTherapeutic targetInflammationEstablished markerNormal adultsPotential mechanismsDiseaseHypertensionMorbidityStatinsArtery